Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
STAR-LLD is a continuous delivery lenalidomide (LLD), which is under clinical development to expand and replace the standard of care for the most common blood cancers, multiple myeloma (MM), and chronic lymphocytic leukemia (CLL).
Lead Product(s): Lenalidomide,Dexamethasone,Bortezomib
Therapeutic Area: Oncology Product Name: STAR-LLD
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2024
Details:
STAR-LLD is a continuous delivery lenalidomide (LLD), which is under phase 1 clinical development to expand and replace the standard of care for the most common blood cancers, multiple myeloma (MM), and chronic lymphocytic leukemia (CLL).
Lead Product(s): Lenalidomide,Dexamethasone,Bortezomib
Therapeutic Area: Oncology Product Name: STAR-LLD
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2024
Details:
STAR-LLD is a continuous delivery lenalidomide in development to expand and replace the standard of care for the most common blood cancers, multiple myeloma (MM) and chronic lymphocytic leukemia (CLL).
Lead Product(s): Lenalidomide,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: STAR-LDD
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2023
Details:
The Company remains focused and committed to the completion of its Phase 1b STAR-LLD clinical trial in multiple myeloma study in order to bring patients a potentially superior delivery of continuous subcutaneous administration of lenalidomide.
Lead Product(s): Lenalidomide,Bortezomib,Dexamethasone
Therapeutic Area: Oncology Product Name: STAR-LDD
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Healthwell Acquisition Corp. I
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination November 03, 2023
Details:
STAR-LLD uses novel treatment modalities of continuous delivery of low-dose lenalidomide. Immunomodulatory drugs (IMiDs) are the mainstay of early treatment in a number of hematologic malignancies – such as multiple myeloma and lymphomas.
Lead Product(s): Lenalidomide
Therapeutic Area: Oncology Product Name: STAR-LLD
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2023
Details:
STAR-LLD uses novel treatment modalities of continuous delivery of low-dose lenalidomide, which is investigated for the treatment of multiple myeloma and lymphomas.
Lead Product(s): Lenalidomide
Therapeutic Area: Oncology Product Name: STAR-LLD
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2023
Details:
Under the agreement, Starton will conduct its Phase 1b trial of STAR-LLD, a continuous delivery lenalidomide in development to replace the standard of care for multiple myeloma and chronic lymphocytic leukemia in multiple myeloma, with a global CRO.
Lead Product(s): Lenalidomide
Therapeutic Area: Oncology Product Name: STAR-LLD
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 10, 2023
Details:
STAR-LLD uses novel treatment modalities of continuous delivery of low-dose lenalidomide. Immunomodulatory drugs (IMiDs) are the mainstay of early treatment in a number of hematologic malignancies – such as multiple myeloma and lymphomas.
Lead Product(s): Lenalidomide
Therapeutic Area: Oncology Product Name: STAR-LLD
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2023
Details:
The data suggest that changing the delivery of lenalidomide to a continuous subcutaneous infusion improves tumor control and tumor volume in lenalidomide resistant tumors.
Lead Product(s): Lenalidomide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
Details:
The investment provides the shareholders with exposure to a rapidly developing therapeutics business, which just reported positive data from a phase 1 clinical trial evaluating the pharmacokinetics and safety of the company’s continuous delivery lenalidomide program.
Lead Product(s): Psychedelic-based Therapeutic
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Love Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 08, 2022